Bharat Biotech

Bharat Biotech needle-free intranasal Covid vaccine is approved for emergency use

Health Health

According to Union Health Minister Mansukh Mandaviya, the needle-free intranasal vaccine of Bharat Biotech against COVID-19 has received approval for use in emergencies in India. The new vaccine can be administered via the nasal route, making it a more advantageous and safe choice.

The minister wrote, “Big Boost to India’s Fight Against COVID-19! Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in the 18+ age group for restricted use in emergency situations. ”

“This step will further strengthen our collective fight against the pandemic. India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji’s leadership. With the science-driven approach & Sabka Prayas, we will defeat COVID-19.”

Bharat Biotech

The rationale behind the intranasal route platform is that both influenza and Covid-19 follow the same pattern of infection, using the nose and mouth to enter the lungs, which is why mucosal immunity is important. The vaccine will also use this nasal (drop) route.

The intranasal vaccine has a number of advantages, according to the manufacturer, including the fact that it is non-invasive (needle-free), simple to administer, and does not require trained medical personnel. It also has higher compliance (suits both children and adults well) and is scalable in terms of manufacturing.

For a brand-new chimp-adenovirus, the single-dose intranasal vaccine for COVID-19, Bharat Biotech and Washington University School of Medicine in St. Louis signed a licensing agreement in September 2020.

The company requested permission from the national drug regulator to begin conducting human clinical trials in January of last year. According to those with knowledge of the situation, the phase 3 trial involved nearly 900 participants and was conducted at nine sites across the nation.

The trial sites included Prakhar Hospital in Kanpur, Rana Hospital in Gorakhpur, Aatman Hospital in Ahmedabad (Gujarat), PGIMS in Rohtak (Haryana), and All India Institute of Medical Sciences in Delhi and Patna (Bihar) (Uttar Pradesh).

Leave a Reply

Your email address will not be published.